title: [Compliance, efficacy and tolerability of the therapeutic regimen recommended by National Consensus on Tuberculosis].
abstract: BACKGROUND
  To study the degree of adhesion, efficacy, and tolerance of therapeutic guidelines advocated by the National Consensus on tuberculosis.
  
  
  METHODS
  A prospective study of a cohort of 84 patients receiving a diagnosis of tuberculosis in a Basic General Health Area between 1-3-1993 and 28-2-1994 treated with the regimen recommended by the National Council. The patients were evaluated clinically and microbiologically during the treatment and during twelve months follow-up.
  
  
  RESULTS
  Fifty-two patients (61.9%) were male and 32 (38.1%) female, aged 29.9 +/- 19.7 years (r = 1-84 years). Seventy-four (88.1%) were index cases and 10 (11.4%) household contacts. Eight patients (9.5%) were also infected with HIV, 71 (84.5%) presented pulmonary tuberculosis and 13 (15.5%) extrapulmonary forms. Therapeutic compliance was correct in 80 cases (95.2%) and incorrect in 4 (4.8%). It was well-tolerated in 73 patients (91.2%), there was slight toxicity in five (6.3%) and severe in two (2.5%). Seventy-four patients (88.1%) were cured, there was one therapeutic failure (1.2%) and five relapses (6%). Overall mortality was 4.8% and attributable mortality 1.2%.
  
  
  CONCLUSIONS
  Our results seem to confirm a high degree of adhesion, good tolerance and acceptable therapeutic efficacy of the scheme proposed by the National Council.
authors.affiliation: Unidad de Enfermedades Infecciosas, Hospital Regional Carlos Haya de Málaga.
authors.forename: J D
authors.initials: JD
authors.lastname: Colmenero
authors.forename: M A
authors.initials: MA
authors.lastname: García-Ordoñez
authors.forename: M D
authors.initials: MD
authors.lastname: Sebastián
authors.forename: E
authors.initials: E
authors.lastname: Pérez-Ruiz
authors.forename: J
authors.initials: J
authors.lastname: Sánchez-Lora
authors.forename: J
authors.initials: J
authors.lastname: Sánchez-González
authors.forename: G
authors.initials: G
authors.lastname: Bentabol
authors.forename: C
authors.initials: C
authors.lastname: Juárez
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000900:Anti-Bacterial Agents; D000995:Antitubercular Agents / Q000627:therapeutic use*; D002648:Child; D002675:Child, Preschool; D004359:Drug Therapy, Combination / Q000627:therapeutic use*; D005260:Female; D015658:HIV Infections / Q000150:complications; D006801:Humans; D007223:Infant; D007538:Isoniazid / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D010349:Patient Compliance; D011446:Prospective Studies; D011718:Pyrazinamide / Q000627:therapeutic use*; D012008:Recurrence; D012293:Rifampin / Q000627:therapeutic use*; D014376:Tuberculosis / Q000150:complications / Q000188:drug therapy* / Q000401:mortality; D018088:Tuberculosis, Multidrug-Resistant / Q000150:complications / Q000188:drug therapy / Q000453:epidemiology
chemical_list: D000900:Anti-Bacterial Agents; D000995:Antitubercular Agents; D011718:Pyrazinamide; D007538:Isoniazid; D012293:Rifampin
vernacular_title: Cumplimiento, eficacia y tolerancia de la pauta terapéutica preconizada por el Consenso Nacional sobre la Tuberculosis.